Japan’s LTT-Biopharma To Commence Phase II For PC-SOD
This article was originally published in PharmAsia News
Executive Summary
LTT Bio-Pharma Co. Ltd will start a Phase II trial for inhalant PC-SOD (recombinant midismase) for the treatment of idiopathic pulmonary fibrosis.